Global Partners L.P. (GLP)
NYSE NYSE Primary 
Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition
Amylyx Pharmaceuticals, Inc.'s relyvrio for ALS was voluntarily delisted in the U.S. and Canada, but has a chance to target this indication with the advancement of AMX0114; IND filing and trial initiation expected in 2024. Full data from the phase 2 HELIOS trial, using AMX0035 to treat patients with Wolfram syndrome, is expected Fall of 2024. Interim analysis from phase 3 ORION study, using AMX0035 to treat patients with progressive supranuclear palsy, expected mid-2025.
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s
Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drugs.
GLP-1 drugs and other constraints in Kroger's pharmacies are crimping profits
Grocery-store chain Kroger Co. on Thursday reported better-than-expected first-quarter results, helped in part by more enthusiasm from wealthier shoppers, but executives warned that difficulties in the company's pharmacies would hit second-quarter profits.
Eli Lilly's Stock Surge Driven by GLP-1 Demand
Most of the market focuses on the technology sector, with names like Nvidia Co. NASDAQ: NVDA receiving the lion's share. Among this hype and excitement, those companies worthy of investor capital have been left behind, particularly those in the ‘defensive' space, such as the healthcare sector.
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
Weight Loss and Blood Sugar Reduction are Major Efficacy Objectives KELOWNA, BC / ACCESSWIRE / June 18, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX,)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has now hired a contract research organization ("CRO") to oversee execution of the Company's 12-week chronic study GLP-1-H24-4, (the "Study") which will evaluate various DehydraTECH-GLP-1 (glucagon-like peptide) formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction, and more. Study preparations with the CRO have commenced pursuant to an initial start-up agreement under which a number of activities will occur such as full clinical protocol design and writing in consultation with medical experts, regulatory authority submissions, and data management planning.
Hims & Hers: The Undervalued Gem Poised For Growth
As of this article being written, Hims & Hers Health is up around 33% since the announcement that they will offer GLP-1 Injections for as low as $199 a month. Reports that the company has already started shipping out injections to subscribers. HIMS stock is still undervalued despite the recent run-up in price, initiating a Buy rating based on subscriber growth, GLP-1 sales estimates, and increased revenues.
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat Ashkenazi
Eli Lilly has more work it wants to do with the hard-won success from its weight loss and diabetes drugs, Zepbound and Mounjaro, outgoing CFO Anat Ashkenazi told CNBC. The company is working to ramp up manufacturing, expand patient access to the treatments and change long-held misconceptions about obesity.
Madrigal Pharmaceuticals: The GLP-1 Threat May Be Overcooked
Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain after Wolfe Research initiated positive coverage. Competition from GLP-1 agonists like Eli Lilly's tirzepatide and Novo Nordisk's semaglutide are expected to pose a threat to Rezdiffra's commercial success.
Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study
Second study arm dosing is now complete. KELOWNA, BC / ACCESSWIRE / June 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") continues to make progress and the second round of dosing for all nine study participants is now complete.
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. NYSE: HIMS provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments for erectile dysfunction (ED) through brand and generic versions of Pfizer Inc. NYSE: PFE Viagra (Sildenafil) and Eli Lilly & Co. NYSE: LLY Cialis (Tadalafil).
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run
The vast majority of patients using GLP-1 agonists such as Ozempic and Wegovy are being treated for diabetes or chronic weight management. GLP-1 medications are believed to have further applications, and Wegovy just gained FDA approval to treat people with heart disease.
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
As weight loss drugs are gaining popularity a new way to invest in the companies behind these products has launched with the Roundhill GLP 1 And Weight Loss ETF (NASDAQ:OZEM). Let's get into everything investors need to know about this new weight loss exchange-traded fund (ETF) before investing in OZEM stock below!
